Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 29 results found. Search for [ Trastuzumab ]

Results 1 to 21 of 29
PTI
April 10, 2019



PTI
February 27, 2019



PB Jayakumar
New Delhi, January 9, 2019
Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide


PB Jayakumar
December 19, 2018
Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.


PTI
December 19, 2018



E. Kumar Sharma
New Delhi, October 29, 2018
A little alertness and some healthy changes in lifestyle can go a long way in dealing with cancer risks.


E Kumar Sharma
New Delhi, October 25, 2018
Kiran Mazumdar-Shaw said Biocon delivered a strong revenue growth of 35 per cent this quarter, driven by robust performance across our biologics, small molecules and research services segments.


PTI
October 25, 2018



E Kumar Sharma
New Delhi, April 27, 2018
While Biocon's Q4 results show margins below expectations, the market is more focused on the company's progress on the biosimilar front.


PTI
January 10, 2018



PTI
January 10, 2018



PTI
January 10, 2018



PTI
January 4, 2018



PTI
December 29, 2017



PTI
December 2, 2017
Ogivri is the first United States Food and Drug Administration (USFDA) approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US, the two companies said in a joint statement.


PTI
July 14, 2017
Drug majors Mylan and Biocon today said the US health regulator's Oncologic Drugs Advisory Committee (ODAC) has recommended approval for their proposed biosimilar trastuzumab, indicated for breast cancer treatment.


Mail Today Bureau
New Delhi, June 28, 2017
Ahead of the GST rollout on July 1, the National Pharmaceutical Pricing Authority (NPPA) on Tuesday announced provisional ceiling prices of 761 medicines which includes a list of antibiotics and drugs for treating cancer, HIV, diabetes.


E. Kumar Sharma
New Delhi, June 10, 2017
Dr. Reddy's says it has a plan and a product pipeline to drive growth in spite of regulatory and other challenges. Can it pull it off?


Team BT
Delhi, September 17, 2016
A brief look at the women in BTs elite club


By E. Kumar Sharma
Delhi, July 23, 2016
Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?


PAGES 1 OF 2  12